Erasca Partners with Merck for KEYTRUDA Combination Trial of Pan-RAS Molecular Glue ERAS-0015
ERAS has more than doubled off its 52-week low of $1.06.
Summary
Erasca, Inc. announced a significant clinical trial collaboration and supply agreement with Merck to evaluate its pan-RAS molecular glue, ERAS-0015, in combination with Merck's blockbuster anti-PD-1 therapy, KEYTRUDA. Under the agreement, Erasca will sponsor the AURORAS-1 proof-of-concept study, with Merck supplying KEYTRUDA at no cost. This partnership provides substantial validation for Erasca's lead oncology candidate, ERAS-0015, especially following the positive preliminary Phase 1 data reported in late April. For Erasca, this collaboration with a major pharmaceutical company like Merck de-risks the development pathway and could accelerate the potential for ERAS-0015 in RAS-mutant solid tumors. Investors will closely watch the progress and initial data from the AURORAS-1 study as a key catalyst for Erasca's stock.
At the time of this announcement, ERAS was trading at $10.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $1.06 to $24.28. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.